Five-year data from the Phase III POLARIX study (abstract #469) reinforce the potential of Polivy in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) to ...
Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma #782 oral presentation ...
Five-year data from the Phase III POLARIX study (abstract #469) reinforce the potential of Polivy in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP ...
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the positive Phase III INAVO120 results, evaluating Itovebi TM ...
UCB will advance its anti-tau antibody for Alzheimer’s disease solo after Roche and Genentech walked away from the asset known as bepranemab.
UCB granted Roche and its biotech unit Genentech an exclusive worldwide license to bepranemab, then called UCB0107, in 2020 as part of a deal worth around $2 billion in milestones. The agreement ...
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from the open-label, single-arm Phase IV ELEVATUM study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback